Skip to main content
. Author manuscript; available in PMC: 2010 Oct 17.
Published in final edited form as: J Clin Psychopharmacol. 2006 Aug;26(4):419–425. doi: 10.1097/01.jcp.0000227356.31203.8a

TABLE 3.

Adjusted Changes in Postdischarge Outcomes Associated With Medications

Outcomes Medications
Stimulants
 Risperidone
 Olanzapine
 Lithium
 VPA
 α-Agonists
 SSRIs
Effect Test Effect Test Effect Test Effect Test Effect Test Effect Test Effect Test
CBCL Total Problems 3 Mos −23.9 ± 16.4 6.11* −18.3 ± 16.0 3.74† −0.93 ± 22.9 0 8.54 ± 17.7 0.66 4.40 ± 24.2 0.09 18.37 ± 19.8 2.46 −2.26 ± 19.5 0.04
6 Mos 10.47 ± 15.5 1.3 4.47 ± 16.0 0.22 7.90 ± 27.0 0.24 15.46 ± 17.9 2.13 51.52 ± 25.1 11.94* 3.56 ± 19.5 0.09 15.43 ± 18.9 1.89
12 Mos 13.17 ± 19.6 1.31 11.27 ± 19.2 0.99 −19.5 ± 34.5 0.92 −12.3 ± 23.3 0.8 19.45 ± 29.9 1.22 −20.6 ± 22.9 2.33 −5.80 ± 28.0 0.12
CBCL Externalizing 3 Mos −5.10 ± 7.2 1.43 −2.27 ± 7.6 0.26 7.90 ± 11.0 1.46 4.34 ± 8.5 0.75 9.72 ± 11.4 2.07 0.78 ± 9.1 0.02 0.36 ± 9.6 0
6 Mos 2.25 ± 6.6 0.33 2.09 ± 6.7 0.28 4.84 ± 11.3 0.52 4.60 ± 7.6 1.03 15.15 ± 9.3 7.6* 0.77 ± 8.0 0.03 6.81 ± 7.9 2.12
12 Mos 5.24 ± 8.2 1.18 1.97 ± 7.8 0.19 0.65 ± 14.4 0.01 −12.3 ± 9.2 5.09* 2.85 ± 10.4 0.22 −10.2 ± 9.3 3.44‡ −9.05 ± 11.0 1.96
CBCL Internalizing 3 Mos −1.69 ± 5.7 0.25 −3.46 ± 5.7 1.03 −1.29 ± 8.5 0.07 11.90 ± 6.5 9.54* 5.85 ± 8.8 1.24 5.03 ± 6.9 1.51 1.75 ± 7.4 0.16
6 Mos 2.05 ± 5.2 0.45 −0.59 ± 5.3 0.04 0.43 ± 9.1 0.01 4.90 ± 6.0 1.91 18.95 ± 7.3 18.92* −0.72 ± 6.3 0.04 3.25 ± 6.4 0.72
12 Mos 3.81 ± 6.0 1.16 2.62 ± 5.6 0.63 −5.72 ± 10.4 0.88 −5.96 ± 6.6 2.37 3.21 ± 7.5 0.53 −4.66 ± 6.8 1.36 −6.16 ± 7.9 1.76
NYPRS Physical Aggression 3 Mos −7.94 ± 5.6 5.74* −7.09 ± 5.8 4.19* −2.66 ± 8.6 0.27 −6.08 ± 6.6 2.44 −7.30 ± 8.7 2.01 3.26 ± 7.0 0.61 −3.89 ± 7.6 0.75
6 Mos 2.86 ± 3.8 1.6 4.29 ± 3.9 3.47‡ 5.31 ± 6.6 1.83 3.33 ± 4.4 1.63 4.72 ± 5.4 2.16 −1.03 ± 4.6 0.14 6.25 ± 4.5 5.41*
12 Mos 0.92 ± 2.7 0.34 −0.27 ± 2.6 0.03 −3.01 ± 5.0 1.06 −4.56 ± 3.0 6.77* −2.59 ± 3.5 1.56 −1.73 ± 3.1 0.89 −4.44 ± 3.6 4.47*
NYPRS Nonphysical Disruptive 3 Mos −46.2 ± 35.3 4.87* −40.8 ± 36.9 3.47‡ −27.2 ± 54.6 0.7 −30.7 ± 41.4 1.57 −43.0 ± 54.6 1.76 21.42 ± 44.4 0.66 −14.9 ± 47.8 0.28
6 Mos 15.50 ± 21.0 1.54 16.23 ± 21.1 1.68 21.41 ± 36.4 0.98 26.62 ± 24.5 3.35‡ 18.15 ± 30.4 1.01 −0.82 ± 25.8 0 34.79 ± 25.3 5.35*
12 Mos 18.60 ± 15.1 4.36* 12.20 ± 14.3 2.1 −2.64 ± 26.4 0.03 −22.3 ± 16.8 5.06* −1.62 ± 19.1 0.02 −20.4 ± 17.2 4.03‡ −26.1 ± 20.4 4.72*

Columns labeled “Effect” show the mean difference between children treated with the medication minus those not treated with it, adjusted for their scores at admission and for concurrently administered medications. Parentheses contain the 95% confidence interval for the adjusted mean difference.

Columns labeled “Test” indicate F values for continuous variables and likelihood ratio χ2 for odds ratios.

*

P < 0.01.

†

P < 0.05.

‡

P < 0.10.